MedTrace Logo

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

NCT03668431 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-06-27

No results posted yet for this study

Summary

This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation.

The names of the study drugs involved in this study are:

* Dabrafenib
* Trametinib
* PDR001

Conditions

Interventions

DRUG

Dabrafenib

Dabrafenib will be taken twice a day for 28 consecutive days .

DRUG

Trametinib

Trametinib will be taken once a day for 28 consecutive days

DRUG

PDR001

PDR001 will be administered IV every 28 days

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Stand Up To Cancer

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Ryan Corcoran, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2022-09-01
Completion
2022-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03668431 on ClinicalTrials.gov